160 related articles for article (PubMed ID: 9711730)
1. Is stereotactic surgical treatment still necessary for Parkinson's disease in the contemporary trend of medical therapy with dopamine receptor agonist?
Amano K; Takakura K
Stereotact Funct Neurosurg; 1997; 69(1-4 Pt 2):5-18. PubMed ID: 9711730
[TBL] [Abstract][Full Text] [Related]
2. Pergolide and Parkinson's disease: new preparation. No clear benefit.
Prescrire Int; 2000 Dec; 9(50):177-9. PubMed ID: 11475497
[TBL] [Abstract][Full Text] [Related]
3. A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists: application to pergolide and bromocriptine.
Bonnet AM; Serre I; Marconi R; Agid Y; Dubois B
Mov Disord; 1995 Sep; 10(5):668-71. PubMed ID: 8552122
[TBL] [Abstract][Full Text] [Related]
4. Modification of dopamine D2 receptor activity by pergolide in Parkinson's disease: an in vivo study by PET.
Linazasoro G; Obeso JA; Gómez JC; Martínez M; Antonini A; Leenders KL
Clin Neuropharmacol; 1999; 22(5):277-80. PubMed ID: 10516878
[TBL] [Abstract][Full Text] [Related]
5. Treatment of early Parkinson's disease: are complicated strategies justified?
Ahlskog JE
Mayo Clin Proc; 1996 Jul; 71(7):659-70. PubMed ID: 8656708
[TBL] [Abstract][Full Text] [Related]
6. Pergolide mesylate: four years experience in Parkinson's disease.
Tanner CM; Goetz CG; Glantz RH; Klawans HL
Adv Neurol; 1987; 45():547-9. PubMed ID: 3825732
[No Abstract] [Full Text] [Related]
7. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study.
Oertel WH; Wolters E; Sampaio C; Gimenez-Roldan S; Bergamasco B; Dujardin M; Grosset DG; Arnold G; Leenders KL; Hundemer HP; Lledó A; Wood A; Frewer P; Schwarz J
Mov Disord; 2006 Mar; 21(3):343-53. PubMed ID: 16211594
[TBL] [Abstract][Full Text] [Related]
8. [A comparative study of the effect of bromocriptine and pergolide on Parkinson disease].
de Yébenes JG; García-Ruiz PJ; Sánchez-Pernaute R
Rev Neurol; 1997 Sep; 25(145):1343-5. PubMed ID: 9377286
[TBL] [Abstract][Full Text] [Related]
9. International symposium on early dopamine agonist therapy of Parkinson's disease.
Arch Neurol; 1988 Feb; 45(2):204-8. PubMed ID: 3341935
[No Abstract] [Full Text] [Related]
10. Double-blind controlled study of pergolide mesylate as an adjunct to Sinemet in the treatment of Parkinson's disease.
Olanow CW; Alberts MJ
Adv Neurol; 1987; 45():555-60. PubMed ID: 3548266
[No Abstract] [Full Text] [Related]
11. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
[TBL] [Abstract][Full Text] [Related]
12. Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study.
Ries V; Selzer R; Eichhorn T; Oertel WH; Eggert K;
Clin Neuropharmacol; 2010 May; 33(3):142-50. PubMed ID: 20502133
[TBL] [Abstract][Full Text] [Related]
13. Analysis of mortality in pergolide-treated patients with Parkinson's disease.
Sayler ME; Street JS; Bosomworth JC; Potvin JH; Kotsanos JG
Neuroepidemiology; 1996; 15(1):26-32. PubMed ID: 8719046
[TBL] [Abstract][Full Text] [Related]
14. Dopamine agonists in the treatment of Parkinson's disease.
Pahwa R; Koller WC
Cleve Clin J Med; 1995; 62(4):212-7. PubMed ID: 7641388
[TBL] [Abstract][Full Text] [Related]
15. Increased plasma arginine vasopressin levels in dopamine agonist-treated Parkinson's disease patients.
Arai M
Neuro Endocrinol Lett; 2011; 32(1):39-43. PubMed ID: 21407160
[TBL] [Abstract][Full Text] [Related]
16. [Pergolide: a useful agonist for the treatment of Parkinson disease].
Bonnet AM; Houeto JL
Rev Neurol (Paris); 2002 Jul; 158(6-7):744-5. PubMed ID: 12486908
[TBL] [Abstract][Full Text] [Related]
17. A crossover, controlled study comparing pergolide with bromocriptine as an adjunct to levodopa for the treatment of Parkinson's disease.
Pezzoli G; Martignoni E; Pacchetti C; Angeleri V; Lamberti P; Muratorio A; Bonuccelli U; De Mari M; Foschi N; Cossutta E
Neurology; 1995 Mar; 45(3 Suppl 3):S22-7. PubMed ID: 7715793
[TBL] [Abstract][Full Text] [Related]
18. Valvular heart disease in patients with Parkinson's disease treated with pergolide, levodopa or both.
Ozer F; Tiras R; Cetin S; Ozturk O; Aydemir T; Ozben S; Meral H; Kizkin S; Bader H; Ozben B
J Clin Neurosci; 2009 Jan; 16(1):83-7. PubMed ID: 19014887
[TBL] [Abstract][Full Text] [Related]
19. Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study.
Pezzoli G; Martignoni E; Pacchetti C; Angeleri VA; Lamberti P; Muratorio A; Bonuccelli U; De Mari M; Foschi N; Cossutta E
Mov Disord; 1994 Jul; 9(4):431-6. PubMed ID: 7969210
[TBL] [Abstract][Full Text] [Related]
20. High doses of pergolide improve clinical global impression in advanced Parkinson's disease:- a preliminary open label study.
Arnold G; Gasser T; Storch A; Lipp A; Kupsch A; Hundemer HP; Schwarz J
Arch Gerontol Geriatr; 2005; 41(3):239-53. PubMed ID: 16029905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
